SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
Publication
, Conference
Lawitz, E; Rodriguez-Torres, M; Rustgi, VK; Hassanein, T; Rahimy, MH; Crowley, CA; Freddo, JL; Muir, AJ; McHutchison, JG
Published in: HEPATOLOGY
October 1, 2010
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2010
Volume
52
Issue
4
Start / End Page
334A / 335A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Lawitz, E., Rodriguez-Torres, M., Rustgi, V. K., Hassanein, T., Rahimy, M. H., Crowley, C. A., … McHutchison, J. G. (2010). SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS. In HEPATOLOGY (Vol. 52, pp. 334A-335A). Boston, MA: WILEY-BLACKWELL.
Lawitz, Eric, Maribel Rodriguez-Torres, Vinod K. Rustgi, Tarek Hassanein, Mohamad H. Rahimy, Constance A. Crowley, James L. Freddo, Andrew J. Muir, and John G. McHutchison. “SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS.” In HEPATOLOGY, 52:334A-335A. WILEY-BLACKWELL, 2010.
Lawitz E, Rodriguez-Torres M, Rustgi VK, Hassanein T, Rahimy MH, Crowley CA, et al. SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS. In: HEPATOLOGY. WILEY-BLACKWELL; 2010. p. 334A-335A.
Lawitz, Eric, et al. “SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS.” HEPATOLOGY, vol. 52, no. 4, WILEY-BLACKWELL, 2010, pp. 334A-335A.
Lawitz E, Rodriguez-Torres M, Rustgi VK, Hassanein T, Rahimy MH, Crowley CA, Freddo JL, Muir AJ, McHutchison JG. SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS. HEPATOLOGY. WILEY-BLACKWELL; 2010. p. 334A-335A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2010
Volume
52
Issue
4
Start / End Page
334A / 335A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics